AC
APLS

AXQ Capital’s Apellis Pharmaceuticals APLS Stock Holding History

AXQ Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,314
Closed -$384K – 427
2024
Q3 		$384K Buy
+13,314
New +$493K 0.12% 299
2024
Q2 		– Sell
-6,900
Closed -$406K – 452
2024
Q1 		$406K Buy
+6,900
New +$440K 0.1% 359
2023
Q3 		– Sell
-2,770
Closed -$252K – 462
2023
Q2 		$252K Buy
+2,770
New +$239K 0.31% 147

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AXQ Capital's APLS Position: Q4 2024 in Review

AXQ Capital sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 13,314 shares — an estimated $384K sold.

AXQ Capital first reported a position in APLS in Q2 2023 and held it in 3 quarters. The position peaked at $406K in Q1 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • AXQ Capital reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • AXQ Capital sold 13,314 Apellis Pharmaceuticals shares in Q4 2024, an estimated $384K.
  • AXQ Capital first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • AXQ Capital's Apellis Pharmaceuticals position peaked at $406K in Q1 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on AXQ Capital's 13F filing for Q4 2024, filed 11 Feb 2025.